• Thomas M Tzschentke, Ulrich Jahnel, Babette Kogel, Thomas Christoph, Werner Englberger, Jean De Vry, Klaus Schiene, Akiko Okamoto, David Upmalis, Horst Weber, Claudia Lange, Jens-Ulrich Stegmann, and Regina Kleinert.
• Grunenthal GmbH, Aachen, Germany. thomas.tzschentke@grunenthal.com
• Drugs Today. 2009 Jul 1;45(7):483-96.

AbstractTapentadol exerts its analgesic effects through micro opioid receptor agonism and noradrenaline reuptake inhibition in the central nervous system. Preclinical studies demonstrated that tapentadol is effective in a broad range of pain models, including nociceptive, inflammatory, visceral, mono- and polyneuropathic models. Moreover, clinical studies showed that tapentadol effectively relieves moderate to severe pain in various pain care settings. In addition, it was reported to be associated with significantly fewer treatment discontinuations due to a significantly lower incidence of gastrointestinal-related adverse events compared with equivalent doses of oxycodone. The combination of these reduced treatment discontinuation rates and tapentadol efficacy for the relief of moderate to severe nociceptive and neuropathic pain may offer an improvement in pain therapy by increasing patient compliance with their treatment regimen.Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.

This article appears in the collection: Tapentadol.

22 keywords...

hide…